Citation Impact
Citing Papers
Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program
2007 StandoutNobel
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
2007
Infrared molecular fingerprinting of blood-based liquid biopsies for the detection of cancer
2021 StandoutNobel
Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice
2023 StandoutNobel
Progress and challenges towards targeted delivery of cancer therapeutics
2018 Standout
Engineering precision nanoparticles for drug delivery
2020 Standout
In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags
2007 Standout
Protein nanoparticles as drug carriers in clinical medicine
2008
Protein‐Based Nanomedicine Platforms for Drug Delivery
2009
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease.
1997
Multifunctional Albumin Nanoparticles As Combination Drug Carriers for Intra‐Tumoral Chemotherapy
2013
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Emerging implications of nanotechnology on cancer diagnostics and therapeutics
2006
Drug penetration in solid tumours
2006 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy
2008
Liquid biopsy enters the clinic — implementation issues and future challenges
2021
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
2018 Standout
Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide
2000
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2014 Standout
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects
2008
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors
2007
Nano based drug delivery systems: recent developments and future prospects
2018 Standout
Fcγ receptors as regulators of immune responses
2007 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery
2010 Standout
A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer
2014
Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: A focus on nano-albumin-bound drugs
2013
Neurological adverse effects caused by cytotoxic and targeted therapies
2009
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
2012 Standout
Crystal structure of the soluble form of the human Fcgamma -receptor IIb: a new member of the immunoglobulin superfamily at 1.7Aresolution
1999
Strategies in the design of nanoparticles for therapeutic applications
2010 Standout
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer
2007
The Multifunctional Fish Gill: Dominant Site of Gas Exchange, Osmoregulation, Acid-Base Regulation, and Excretion of Nitrogenous Waste
2004 Standout
Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review
2011
Emerging use of nanoparticles in diagnosis and treatment of breast cancer
2006
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
2015 Standout
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
2008 Standout
Small-cell lung cancer
2005
Gold Nanorods: From Synthesis and Properties to Biological and Biomedical Applications
2009 Standout
Idelalisib: First Global Approval
2014
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
FcRn: the neonatal Fc receptor comes of age
2007 Standout
Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non–Small-Cell Lung Cancer as Frontline and Second-Line Therapy
2010
Endocytosis of nanomedicines
2010 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy
2007
DLS and zeta potential – What they are and what they are not?
2016 Standout
Albumin-bound paclitaxel: a next-generation taxane
2006
Modeling neurodevelopmental disorder-associated humanAGO1mutations inCaenorhabditis elegansArgonautealg-1
2024 StandoutNobel
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
Energization of sodium absorption by the H+-ATPase pump in mitochondria-rich cells of frog skin
1992
Therapeutic Nanoparticles for Drug Delivery in Cancer
2008 Standout
Nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer
2010
Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities
2022
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
2009
Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients With Advanced Nonhematologic Malignancies
2005
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Nanoparticle Albumin-Bound Paclitaxel (Abi-007): A Newer Taxane Alternative In Breast Cancer
2005
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel andnab-Paclitaxel
2008
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
2017 Standout
Nanoparticles in Photodynamic Therapy
2015 Standout
Silver Nanoparticles: Synthesis, Characterization, Properties, Applications, and Therapeutic Approaches
2016 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)
2015
HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory
2019
Analysis of nanoparticle delivery to tumours
2016 Standout
Cellular uptake of nanoparticles: journey inside the cell
2017 Standout
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2015
Photothermal Nanomaterials: A Powerful Light-to-Heat Converter
2023 Standout
Clinical Translation of Nanomedicine
2015
Works of Ray D. Page being referenced
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
2019
New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen.
1998
Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer
2012
Dose‐dense vinorelbine and docetaxel with Filgrastim support in patients with advanced nonsmall cell lung carcinoma
2005
Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16.
1995
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
2017
Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC).
2013
Morphological Changes in the Skin of Rana pipiens in Response to Metabolic Acidosis
1987
P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153
2017
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).
2014
Multicenter Phase II Trial of ABI-007, an Albumin-Bound Paclitaxel, in Women With Metastatic Breast Cancer
2005
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial
2019